WuXi Healthcare Ventures
VC Fund
Cambridge, United States
WuXi Healthcare Ventures is a VC fund in Cambridge focused on Biotechnology and Health Care. Frontline BioVentures merged with WuXi Healthcare Ventures to form 6 Dimensions Capital.
- Total investments:
- 39
- Last investment:
- Lead investor:
- 15%
- Fund size:
- $290M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries WuXi Healthcare Ventures invests in
Stages WuXi Healthcare Ventures invests in
Countries WuXi Healthcare Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 23 (59%)
- Health Care 13 (33%)
- Therapeutics 10 (26%)
- Pharmaceutical 10 (26%)
- Medical 9 (23%)
Stage
- Series B 14 (36%)
- Series A 13 (33%)
- Series C 6 (15%)
- Series D 3 (8%)
- Series E 1 (3%)
Country
- United States 17 (44%)
- China 8 (21%)
- Israel 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Edward Hu
Founding Partner
|
Founding Partner | Total investments: 5 | Find email | |
Sofie Qiao
Venture Partner
|
Venture Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates indevelopment. | $100M / Series D / Jul 13, 2021 | ||
| Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients. The company is headquartered in Florida, USA. | Series A / Mar 23, 2021 | ||
| Discovering powerful new drugs from eukaryotic microbes by combining Genomics with AI and Synthetic Biology. Founded by Gregory Verdine, PhD, Rick Klausner, MD and WeiQing Zhou, MBA, LifeMine Therapeutics is headquartered in Cambridge, Massachusetts. | $50M / Series B / Jan 07, 2021 | ||
| XW Laboratories is an Asia-Pacific biopharmaceutical company dedicated to discovering and developing transformational medicines that will markedly improve the quality of life in patients suffering from neurological disorders.Founded in 2014, XW Laboratories has developed 3 unique drug R&D platforms that not only allow us to improve uponexisting medication through approaches such as prodrug and functional group switch, but also be at the forefront of medicinal technology in immunoneurology through the application of their mitochondria-targeting platform. | $40M / Series C / Sep 18, 2020 | ||
Halda Therapeutics
|
Halda Therapeutics is a research-stage drug discovery company, seeking to create the next generation of precision medicine based on a novel therapeutic modality which may be a platform for a number of disease states. | $25M / Series A / Feb 01, 2019 | |
| Antengene is a developer of biotechnology and bio-pharmaceuticals intended to provide medicine treatment for tumor.The company focuses on providing patients with innovative anti-tumor and anti-cancer therapies through new drug development, clinical research and drug production, enabling physicians to meet unmet medical needs in Asia. | $120M / Series B / Jan 02, 2019 | ||
| Refuge is a cancer immunotherapy company leveraging synthetic biology and gene engineering to unlock the full promise of cell therapies. We create cell therapies that sense their surroundings and conditionally activate or repress multiple genes simultaneously – resulting in more potent and targeted treatments beyond a single target and function. | $25M / Series B / May 02, 2018 | ||
| Unity Biotechnology designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. | $55M / Series C / Mar 19, 2018 | ||
| IDEAYA Biosciences (IDEAYA) is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and for enhancing immunotherapy response, and immuno-oncology therapies targeting the tumor micro-environment. IDEAYA, locatedin South San Francisco and La Jolla, California, has assembled leading scientists and advisors with extensive knowledge and expertise in cancer biology and small molecule drug discovery. | $94M / Series B / Mar 15, 2018 | ||
| Medeor Therapeutics is a developer of cellular immunotherapies designed to improve outcomes in organ transplant recipients. The company's cellular immunotherapies consist of approaches to organ transplant immune tolerance and immuno-oncology, enabling healthcare providers to preserve or improve transplant kidney function and prevent graftrejection better than currently available immunosuppression (anti-rejection) drugs. | $57M / Series B / Nov 27, 2017 | ||
| See all 39 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does WuXi Healthcare Ventures invest in?
WuXi Healthcare Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 39 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact WuXi Healthcare Ventures?
Public channels for WuXi Healthcare Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at WuXi Healthcare Ventures?
The team at WuXi Healthcare Ventures includes Edward Hu (Founding Partner) and Sofie Qiao (Venture Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
